|Posted date||Feb 22, 2008|
|Date of filing||Aug 10, 2006|
|Date of publication of application||Feb 21, 2008|
|Date of registration||Dec 7, 2012|
PROBLEM TO BE SOLVED: To provide a tumor marker, especially a cancer marker, and to provide a screening method of a new anticancer agent by using the tumor marker.
SOLUTION: CXCL16 is highly expressed not only in colon cancer but also in human lung cancer, breast cancer or the like, and measured in the body fluid to enable the CXCL16 to be used as a new marker for judging the presence or absence of the onset, the degree of the progress, and the condition of the prognosis of the cancer. The CXCL16 exhibits dye-affinity limited to a highly manifested cancer part in immunostaining, and the expression is recognized to have correlation with lymphocytic infiltration. The strong expression group is good in prognosis, and the CXCL16 is highly useful as the prognosis marker.
|Outline of related art and contending technology||
|Field of industrial application||
|Scope of claims||
|IPC(International Patent Classification)|
|State of application right||Registered|
Contact Information for " TUMOR MARKER"
- University of TOYAMA Tomidai TLO
- URL: https://sanren.ctg.u-toyama.ac.jp/
- Address: 3190 Gofuku, Toyama-shi, Toyama, Japan , 930-8555
- Phone: 81-76-445-6392
- Fax: 81-76-445-6939